Skip to main content
Fig. 4 | BMC Complementary Medicine and Therapies

Fig. 4

From: Baicalein inhibits inflammatory response and promotes osteogenic activity in periodontal ligament cells challenged with lipopolysaccharides

Fig. 4

Baicalein acts as the MAPK signaling inhibitor to down-regulate the expressions of inflammatory mediators of PDLCs challenged with LPS. The western blot results showed that LPS induced the phosphorylation of MAPK family proteins (ERK, JNK and p38) could be inhibited by baicalein (a). The inhibition of MAPK signaling (PD98059, PD, ERK inhibitor; SP600125, SP, JNK inhibitor; SB203580, SB, p38 inhibitor) significantly reduced the mRNA expressions (b) and protein concentrations (c) of IL-1β, TNF-α, MCP-1, MMP-1 and MMP-2. *p < 0.05, **p < 0.01, statistical significant difference in comparison to cells treated with LPS alone

Back to article page
\